Last 48 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 17.57 | 18.63 | 25.47 | 15.90 | 14.64 | 11.21 | 11.62 | 14.25 | 14.02 | 13.61 | 9.31 | 12.61 | 10.50 | 10.53 | 11.52 | 26.04 | 10.66 | 24.44 | 8.92 | 22.99 | 13.49 |
| — | +66.3% | +119.1% | +11.6% | +4.4% | -17.7% | +24.9% | +13.0% | +33.6% | +29.3% | -19.2% | -51.6% | -1.5% | -56.9% | +29.2% | +13.3% | -21.0% | +98.9% | -87.0% | +32.7% | +105.2% | |
| P/S Ratio | 6.53 | 7.92 | 8.95 | 7.38 | 6.20 | 4.34 | 4.71 | 5.84 | 5.79 | 5.29 | 4.21 | 4.45 | 4.61 | 4.58 | 5.48 | 6.99 | 4.94 | 6.07 | 4.63 | 6.22 | 4.94 |
| — | +82.3% | +89.9% | +26.5% | +7.1% | -17.9% | +11.9% | +31.1% | +25.7% | +15.5% | -23.1% | -36.3% | -6.8% | -24.5% | +18.3% | +12.4% | +0.0% | +27.7% | -9.5% | +39.9% | +66.7% | |
| P/B Ratio | 3.30 | 3.88 | 4.74 | 3.29 | 3.01 | 1.93 | 2.20 | 2.67 | 2.84 | 2.66 | 2.14 | 1.83 | 1.97 | 2.02 | 2.17 | 2.86 | 2.24 | 2.62 | 2.05 | 2.61 | 2.29 |
| — | +100.4% | +115.5% | +23.3% | +5.8% | -27.2% | +2.9% | +45.7% | +44.7% | +31.5% | -1.4% | -36.1% | -12.1% | -23.1% | +5.8% | +9.8% | -2.6% | +12.6% | -9.0% | +29.4% | +67.2% | |
| P/FCF | 19.96 | 30.17 | 19.30 | 33.67 | 14.10 | 26.79 | 9.70 | 16.88 | 14.42 | 20.22 | 8.44 | 38.02 | 10.01 | 44.35 | 8.33 | 38.72 | 13.43 | 25.76 | 7.77 | 24.83 | 13.53 |
| — | +12.6% | +99.1% | +99.5% | -2.2% | +32.5% | +14.9% | -55.6% | +44.1% | -54.4% | +1.3% | -1.8% | -25.5% | +72.2% | +7.1% | +55.9% | -0.8% | +60.2% | -68.3% | +65.2% | +182.5% | |
| EV / EBITDA | 12.01 | 15.32 | 19.31 | 14.34 | 11.36 | 7.97 | 8.25 | 10.46 | 11.17 | 10.54 | 7.25 | 9.54 | 8.02 | 8.17 | 9.02 | 17.98 | 7.66 | 13.22 | 7.11 | 14.03 | 9.00 |
| — | +92.3% | +134.2% | +37.2% | +1.7% | -24.4% | +13.8% | +9.7% | +39.3% | +29.1% | -19.7% | -47.0% | +4.7% | -38.2% | +26.9% | +28.2% | -14.8% | +48.6% | — | -36.3% | +80.9% | |
| EV / EBIT | 12.69 | 15.32 | 20.94 | 12.20 | 10.60 | 7.39 | 7.96 | 9.76 | 10.15 | 9.73 | 6.53 | 8.41 | 7.43 | 7.61 | 8.79 | 18.36 | 7.79 | 18.08 | 6.82 | 15.12 | 10.38 |
| — | +107.3% | +163.2% | +25.0% | +4.4% | -24.0% | +21.7% | +16.1% | +36.6% | +27.7% | -25.6% | -54.2% | -4.7% | -57.9% | +28.9% | +21.4% | -24.9% | +91.7% | -86.9% | -41.9% | +98.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 87.9% | 87.3% | 82.9% | 86.9% | 87.4% | 89.0% | 88.4% | 89.7% | 88.9% | 89.1% | 89.2% | 88.4% | 88.5% | 89.3% | 89.7% | 88.6% | 92.8% | 93.6% | 94.4% | 91.7% | 93.8% |
| — | -1.9% | -6.1% | -3.1% | -1.7% | -0.1% | -1.0% | +1.4% | +0.5% | -0.2% | -0.5% | -0.2% | -4.6% | -4.7% | -5.0% | -3.3% | -1.0% | +2.1% | +0.5% | +0.8% | +0.1% | |
| Operating Margin | 47.7% | 42.2% | 41.7% | 45.2% | 48.7% | 45.6% | 48.2% | 48.6% | 45.8% | 44.7% | 52.6% | 42.3% | 53.7% | 52.5% | 56.1% | 35.7% | 60.9% | 43.2% | 62.4% | 40.9% | 51.4% |
| — | -7.5% | -13.5% | -6.9% | +6.3% | +2.0% | -8.3% | +14.9% | -14.6% | -14.8% | -6.3% | +18.4% | -11.9% | +21.6% | -10.0% | -12.6% | +18.4% | -13.1% | +464.8% | +141.1% | -11.6% | |
| Net Margin | 41.9% | 42.5% | 35.2% | 46.1% | 42.4% | 38.8% | 40.6% | 40.9% | 41.3% | 38.9% | 45.2% | 35.3% | 43.9% | 43.5% | 47.5% | 26.9% | 46.4% | 24.8% | 51.9% | 27.0% | 36.6% |
| — | +9.7% | -13.3% | +12.6% | +2.6% | -0.4% | -10.3% | +15.9% | -6.0% | -10.5% | -4.8% | +31.4% | -5.3% | +74.9% | -8.5% | -0.5% | +26.8% | -35.7% | +595.7% | +5.3% | -18.8% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.7% | 5.4% | 4.2% | 5.3% | 4.9% | 4.4% | 4.9% | 4.8% | 5.2% | 5.0% | 5.4% | 3.7% | 4.8% | 4.9% | 4.9% | 2.8% | 5.4% | 2.7% | 5.9% | 2.9% | 4.4% |
| — | +22.3% | -13.0% | +10.8% | -6.1% | -12.2% | -10.2% | +29.4% | +8.9% | +2.4% | +11.5% | +31.5% | -10.7% | +80.2% | -17.6% | -2.0% | +23.7% | -43.9% | +612.8% | -2.6% | -18.9% | |
| ROA | 17.5% | 4.8% | 3.8% | 4.8% | 4.4% | 4.0% | 4.3% | 4.2% | 4.5% | 4.2% | 4.5% | 3.1% | 3.9% | 4.0% | 3.9% | 2.2% | 4.2% | 2.1% | 4.6% | 2.2% | 3.3% |
| — | +20.9% | -11.7% | +15.0% | -0.6% | -6.0% | -5.0% | +35.9% | +14.3% | +5.7% | +15.4% | +37.0% | -7.6% | +87.0% | -14.7% | +1.7% | +28.5% | -41.5% | +645.2% | +0.3% | -17.1% | |
| ROIC | 21.4% | 5.3% | 4.7% | 4.9% | 5.3% | 5.1% | 5.7% | 5.4% | 5.3% | 5.0% | 5.3% | 3.6% | 4.7% | 4.7% | 4.5% | 2.9% | 5.4% | 3.6% | 5.4% | 3.4% | 4.8% |
| — | +2.9% | -16.9% | -9.4% | +0.7% | +1.6% | +7.5% | +49.7% | +13.1% | +6.1% | +15.8% | +22.9% | -14.0% | +33.1% | -15.6% | -13.1% | +13.8% | -26.0% | +480.4% | +135.5% | -5.1% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.01 | — | — | 0.01 | — | — | 0.03 | 0.05 | 0.07 | 0.09 | 0.11 | 0.12 | 0.14 | 0.15 | 0.16 | 0.17 | 0.18 | 0.19 | 0.19 | 0.20 | 0.21 |
| — | — | — | -88.6% | — | — | -73.9% | -60.2% | -53.2% | -40.6% | -28.0% | -29.9% | -20.1% | -20.2% | -18.5% | -17.5% | -16.1% | -15.7% | -17.5% | -14.2% | -14.3% | |
| Debt / EBITDA | 0.02 | — | — | 0.10 | — | — | 0.50 | 0.79 | 1.10 | 1.48 | 1.62 | 2.56 | 2.35 | 2.45 | 2.69 | 4.24 | 2.44 | 3.73 | 2.66 | 4.39 | 3.32 |
| — | — | — | -87.6% | — | — | -69.3% | -68.9% | -53.0% | -39.8% | -39.9% | -39.7% | -3.8% | -34.3% | +0.9% | -3.4% | -26.3% | +9.4% | — | -57.0% | -3.4% | |
| Current Ratio | 6.60 | 5.73 | 4.79 | 6.60 | 6.40 | 7.26 | 5.46 | 5.25 | 4.58 | 4.35 | 3.77 | 4.41 | 4.65 | 8.68 | 9.84 | 9.85 | 9.68 | 8.10 | 8.84 | 7.61 | 7.46 |
| — | -21.1% | -12.2% | +25.8% | +39.6% | +66.9% | +44.7% | +18.9% | -1.5% | -49.9% | -61.6% | -55.2% | -52.0% | +7.2% | +11.3% | +29.5% | +29.8% | +8.8% | +32.7% | +13.5% | +3.3% | |
| Quick Ratio | 6.28 | 5.41 | 4.50 | 6.28 | 6.07 | 6.94 | 5.23 | 5.03 | 4.41 | 4.18 | 3.64 | 4.28 | 4.51 | 8.40 | 9.52 | 9.55 | 9.39 | 7.83 | 8.54 | 7.30 | 7.15 |
| — | -22.0% | -14.1% | +24.7% | +37.6% | +65.8% | +43.9% | +17.8% | -2.1% | -50.2% | -61.8% | -55.2% | -52.0% | +7.3% | +11.5% | +30.8% | +31.2% | +9.4% | +34.3% | +13.4% | +4.0% | |
| Interest Coverage | 88.89 | 129.52 | 107.10 | 144.23 | 147.00 | 56.95 | 68.43 | 51.19 | 39.48 | 31.63 | 30.97 | 20.56 | 23.55 | 23.65 | 22.15 | 15.03 | 34.97 | 25.29 | 66.68 | 36.00 | 45.43 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying UTHR stock.
United Therapeutics Corporation's current P/E is 17.6x. The average P/E over the last 4 quarters is 18.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
United Therapeutics Corporation's current operating margin is 47.7%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking United Therapeutics Corporation's business trajectory between earnings reports.